Guardant Health, Inc.
Guardant Health, Inc. (GH) Stock Competitors & Peer Comparison
See (GH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GH | $44.42 | -2.35% | 5.5B | -13.10 | -$3.39 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.57% |
| TMO | $478.32 | +0.69% | 180.5B | 27.66 | $17.29 | +0.34% |
| DHR | $205.48 | +1.32% | 147.2B | 43.63 | $4.71 | +0.57% |
| IDXX | $565.19 | +2.77% | 45.5B | 52.19 | $10.83 | N/A |
| A | $120.18 | -0.14% | 34.1B | 29.60 | $4.06 | +0.81% |
| IQV | $199.17 | -0.82% | 33.9B | 28.88 | $6.90 | N/A |
| MTD | $1,263.99 | +0.26% | 26.2B | 31.50 | $40.09 | N/A |
| NTRA | $138.90 | -1.53% | 19B | -94.49 | -$1.47 | N/A |
| DGX | $168.55 | -1.95% | 18.8B | 20.19 | $8.35 | +1.84% |
Stock Comparison
GH vs DHR-PB Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $44.42, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +3.69%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PB's competition here
GH vs TMO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, TMO has a market cap of 180.5B. Regarding current trading prices, GH is priced at $44.42, while TMO trades at $478.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas TMO's P/E ratio is 27.66. In terms of profitability, GH's ROE is +3.69%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check TMO's competition here
GH vs DHR Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DHR has a market cap of 147.2B. Regarding current trading prices, GH is priced at $44.42, while DHR trades at $205.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DHR's P/E ratio is 43.63. In terms of profitability, GH's ROE is +3.69%, compared to DHR's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR's competition here
GH vs IDXX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, IDXX has a market cap of 45.5B. Regarding current trading prices, GH is priced at $44.42, while IDXX trades at $565.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas IDXX's P/E ratio is 52.19. In terms of profitability, GH's ROE is +3.69%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, GH is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check IDXX's competition here
GH vs A Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, A has a market cap of 34.1B. Regarding current trading prices, GH is priced at $44.42, while A trades at $120.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas A's P/E ratio is 29.60. In terms of profitability, GH's ROE is +3.69%, compared to A's ROE of +0.19%. Regarding short-term risk, GH is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check A's competition here
GH vs IQV Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, IQV has a market cap of 33.9B. Regarding current trading prices, GH is priced at $44.42, while IQV trades at $199.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas IQV's P/E ratio is 28.88. In terms of profitability, GH's ROE is +3.69%, compared to IQV's ROE of +0.20%. Regarding short-term risk, GH is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check IQV's competition here
GH vs MTD Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MTD has a market cap of 26.2B. Regarding current trading prices, GH is priced at $44.42, while MTD trades at $1,263.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MTD's P/E ratio is 31.50. In terms of profitability, GH's ROE is +3.69%, compared to MTD's ROE of +1.21%. Regarding short-term risk, GH is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check MTD's competition here
GH vs NTRA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NTRA has a market cap of 19B. Regarding current trading prices, GH is priced at $44.42, while NTRA trades at $138.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NTRA's P/E ratio is -94.49. In terms of profitability, GH's ROE is +3.69%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, GH is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NTRA's competition here
GH vs DGX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DGX has a market cap of 18.8B. Regarding current trading prices, GH is priced at $44.42, while DGX trades at $168.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DGX's P/E ratio is 20.19. In terms of profitability, GH's ROE is +3.69%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GH is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DGX's competition here
GH vs WAT Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, WAT has a market cap of 18B. Regarding current trading prices, GH is priced at $44.42, while WAT trades at $302.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas WAT's P/E ratio is 27.48. In terms of profitability, GH's ROE is +3.69%, compared to WAT's ROE of +0.39%. Regarding short-term risk, GH is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check WAT's competition here
GH vs ILMN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ILMN has a market cap of 17.3B. Regarding current trading prices, GH is priced at $44.42, while ILMN trades at $109.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ILMN's P/E ratio is -17.98. In terms of profitability, GH's ROE is +3.69%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, GH is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ILMN's competition here
GH vs ICLR Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ICLR has a market cap of 15.1B. Regarding current trading prices, GH is priced at $44.42, while ICLR trades at $187.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ICLR's P/E ratio is 19.26. In terms of profitability, GH's ROE is +3.69%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, GH is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ICLR's competition here
GH vs PKI Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GH is priced at $44.42, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PKI's P/E ratio is 41.45. In terms of profitability, GH's ROE is +3.69%, compared to PKI's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PKI's competition here
GH vs MEDP Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MEDP has a market cap of 12.6B. Regarding current trading prices, GH is priced at $44.42, while MEDP trades at $447.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MEDP's P/E ratio is 33.30. In terms of profitability, GH's ROE is +3.69%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, GH is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MEDP's competition here
GH vs RVTY Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, RVTY has a market cap of 12.2B. Regarding current trading prices, GH is priced at $44.42, while RVTY trades at $103.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas RVTY's P/E ratio is 42.85. In terms of profitability, GH's ROE is +3.69%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check RVTY's competition here
GH vs QGEN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, QGEN has a market cap of 11.2B. Regarding current trading prices, GH is priced at $44.42, while QGEN trades at $51.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas QGEN's P/E ratio is 120.44. In terms of profitability, GH's ROE is +3.69%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check QGEN's competition here
GH vs TEM Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, TEM has a market cap of 10.8B. Regarding current trading prices, GH is priced at $44.42, while TEM trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas TEM's P/E ratio is -12.50. In terms of profitability, GH's ROE is +3.69%, compared to TEM's ROE of -5.31%. Regarding short-term risk, GH is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TEM's competition here
GH vs EXAS Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, EXAS has a market cap of 9.1B. Regarding current trading prices, GH is priced at $44.42, while EXAS trades at $48.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas EXAS's P/E ratio is -8.77. In terms of profitability, GH's ROE is +3.69%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, GH is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check EXAS's competition here
GH vs CRL Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CRL has a market cap of 8.7B. Regarding current trading prices, GH is priced at $44.42, while CRL trades at $176.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CRL's P/E ratio is -294.92. In terms of profitability, GH's ROE is +3.69%, compared to CRL's ROE of -0.01%. Regarding short-term risk, GH is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CRL's competition here
GH vs SYNH Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GH is priced at $44.42, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GH's ROE is +3.69%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check SYNH's competition here
GH vs RDNT Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, GH is priced at $44.42, while RDNT trades at $57.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas RDNT's P/E ratio is -133.49. In terms of profitability, GH's ROE is +3.69%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check RDNT's competition here
GH vs SHC Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, SHC has a market cap of 3.5B. Regarding current trading prices, GH is priced at $44.42, while SHC trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas SHC's P/E ratio is 136.67. In terms of profitability, GH's ROE is +3.69%, compared to SHC's ROE of +0.06%. Regarding short-term risk, GH is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SHC's competition here
GH vs OLK Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GH is priced at $44.42, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas OLK's P/E ratio is -96.59. In terms of profitability, GH's ROE is +3.69%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GH is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OLK's competition here
GH vs TWST Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, TWST has a market cap of 2.2B. Regarding current trading prices, GH is priced at $44.42, while TWST trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas TWST's P/E ratio is -11.07. In terms of profitability, GH's ROE is +3.69%, compared to TWST's ROE of -0.41%. Regarding short-term risk, GH is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TWST's competition here
GH vs VIVO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, GH is priced at $44.42, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas VIVO's P/E ratio is 21.09. In terms of profitability, GH's ROE is +3.69%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, GH is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check VIVO's competition here
GH vs GRAL Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, GRAL has a market cap of 1.4B. Regarding current trading prices, GH is priced at $44.42, while GRAL trades at $40.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas GRAL's P/E ratio is -0.68. In terms of profitability, GH's ROE is +3.69%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, GH is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check GRAL's competition here
GH vs NEOG Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NEOG has a market cap of 1.1B. Regarding current trading prices, GH is priced at $44.42, while NEOG trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NEOG's P/E ratio is -2.34. In terms of profitability, GH's ROE is +3.69%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, GH is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEOG's competition here
GH vs OPK Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, GH is priced at $44.42, while OPK trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas OPK's P/E ratio is -22.83. In terms of profitability, GH's ROE is +3.69%, compared to OPK's ROE of -0.03%. Regarding short-term risk, GH is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OPK's competition here
GH vs CDNA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CDNA has a market cap of 712.2M. Regarding current trading prices, GH is priced at $44.42, while CDNA trades at $12.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CDNA's P/E ratio is 11.42. In terms of profitability, GH's ROE is +3.69%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CDNA's competition here
GH vs GRALV Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GH is priced at $44.42, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas GRALV's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to GRALV's ROE of N/A. Regarding short-term risk, GH is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check GRALV's competition here
GH vs PSNL Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PSNL has a market cap of 574.1M. Regarding current trading prices, GH is priced at $44.42, while PSNL trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PSNL's P/E ratio is -5.04. In terms of profitability, GH's ROE is +3.69%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, GH is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PSNL's competition here
GH vs FLGT Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, FLGT has a market cap of 559.2M. Regarding current trading prices, GH is priced at $44.42, while FLGT trades at $18.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas FLGT's P/E ratio is -13.81. In terms of profitability, GH's ROE is +3.69%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, GH is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check FLGT's competition here
GH vs LAB Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, LAB has a market cap of 529.9M. Regarding current trading prices, GH is priced at $44.42, while LAB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas LAB's P/E ratio is -4.36. In terms of profitability, GH's ROE is +3.69%, compared to LAB's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LAB's competition here
GH vs CSTL Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CSTL has a market cap of 464M. Regarding current trading prices, GH is priced at $44.42, while CSTL trades at $16.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CSTL's P/E ratio is -84.58. In terms of profitability, GH's ROE is +3.69%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, GH is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CSTL's competition here
GH vs MYGN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MYGN has a market cap of 410.2M. Regarding current trading prices, GH is priced at $44.42, while MYGN trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MYGN's P/E ratio is -3.97. In terms of profitability, GH's ROE is +3.69%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, GH is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYGN's competition here
GH vs CO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GH is priced at $44.42, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CO's P/E ratio is 5.06. In terms of profitability, GH's ROE is +3.69%, compared to CO's ROE of +0.11%. Regarding short-term risk, GH is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CO's competition here
GH vs STIM Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, STIM has a market cap of 296.9M. Regarding current trading prices, GH is priced at $44.42, while STIM trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas STIM's P/E ratio is -3.40. In terms of profitability, GH's ROE is +3.69%, compared to STIM's ROE of -2.09%. Regarding short-term risk, GH is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check STIM's competition here
GH vs FLDM Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GH is priced at $44.42, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GH's ROE is +3.69%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check FLDM's competition here
GH vs ACRS Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ACRS has a market cap of 184.1M. Regarding current trading prices, GH is priced at $44.42, while ACRS trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ACRS's P/E ratio is -1.07. In terms of profitability, GH's ROE is +3.69%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, GH is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ACRS's competition here
GH vs NEO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NEO has a market cap of 161.9M. Regarding current trading prices, GH is priced at $44.42, while NEO trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NEO's P/E ratio is -10.31. In terms of profitability, GH's ROE is +3.69%, compared to NEO's ROE of -0.09%. Regarding short-term risk, GH is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEO's competition here
GH vs XGN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, XGN has a market cap of 158.9M. Regarding current trading prices, GH is priced at $44.42, while XGN trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas XGN's P/E ratio is -8.65. In terms of profitability, GH's ROE is +3.69%, compared to XGN's ROE of -1.34%. Regarding short-term risk, GH is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check XGN's competition here
GH vs GTH Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GH is priced at $44.42, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas GTH's P/E ratio is -1.11. In terms of profitability, GH's ROE is +3.69%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GH is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GTH's competition here
GH vs MDXH Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MDXH has a market cap of 123.2M. Regarding current trading prices, GH is priced at $44.42, while MDXH trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MDXH's P/E ratio is -2.39. In terms of profitability, GH's ROE is +3.69%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, GH is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MDXH's competition here
GH vs SERA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, SERA has a market cap of 119.3M. Regarding current trading prices, GH is priced at $44.42, while SERA trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas SERA's P/E ratio is -3.46. In terms of profitability, GH's ROE is +3.69%, compared to SERA's ROE of -0.51%. Regarding short-term risk, GH is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SERA's competition here
GH vs GENE Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GH is priced at $44.42, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas GENE's P/E ratio is -38.25. In terms of profitability, GH's ROE is +3.69%, compared to GENE's ROE of -3.62%. Regarding short-term risk, GH is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GENE's competition here
GH vs ATLN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ATLN has a market cap of 107.9M. Regarding current trading prices, GH is priced at $44.42, while ATLN trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ATLN's P/E ratio is -0.47. In terms of profitability, GH's ROE is +3.69%, compared to ATLN's ROE of -42.96%. Regarding short-term risk, GH is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ATLN's competition here
GH vs PRE Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PRE has a market cap of 104.9M. Regarding current trading prices, GH is priced at $44.42, while PRE trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PRE's P/E ratio is -2.11. In terms of profitability, GH's ROE is +3.69%, compared to PRE's ROE of -0.28%. Regarding short-term risk, GH is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PRE's competition here
GH vs PRENW Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PRENW has a market cap of 101.8M. Regarding current trading prices, GH is priced at $44.42, while PRENW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PRENW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRENW's competition here
GH vs VNRX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, VNRX has a market cap of 77.2M. Regarding current trading prices, GH is priced at $44.42, while VNRX trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas VNRX's P/E ratio is -2.75. In terms of profitability, GH's ROE is +3.69%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, GH is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check VNRX's competition here
GH vs NOTV Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NOTV has a market cap of 76.3M. Regarding current trading prices, GH is priced at $44.42, while NOTV trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NOTV's P/E ratio is -0.71. In terms of profitability, GH's ROE is +3.69%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, GH is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NOTV's competition here
GH vs BDSX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BDSX has a market cap of 65.4M. Regarding current trading prices, GH is priced at $44.42, while BDSX trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BDSX's P/E ratio is -1.65. In terms of profitability, GH's ROE is +3.69%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, GH is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BDSX's competition here
GH vs DRIO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DRIO has a market cap of 29M. Regarding current trading prices, GH is priced at $44.42, while DRIO trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DRIO's P/E ratio is -1.18. In terms of profitability, GH's ROE is +3.69%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, GH is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DRIO's competition here
GH vs STRRP Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, STRRP has a market cap of 28.9M. Regarding current trading prices, GH is priced at $44.42, while STRRP trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas STRRP's P/E ratio is -4.50. In terms of profitability, GH's ROE is +3.69%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, GH is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check STRRP's competition here
GH vs AKU Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GH is priced at $44.42, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas AKU's P/E ratio is -0.13. In terms of profitability, GH's ROE is +3.69%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GH is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check AKU's competition here
GH vs PRPO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PRPO has a market cap of 22M. Regarding current trading prices, GH is priced at $44.42, while PRPO trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PRPO's P/E ratio is -7.05. In terms of profitability, GH's ROE is +3.69%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, GH is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRPO's competition here
GH vs CEMI Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GH is priced at $44.42, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GH's ROE is +3.69%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GH is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CEMI's competition here
GH vs ENZ Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GH is priced at $44.42, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GH's ROE is +3.69%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, GH is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ENZ's competition here
GH vs PMD Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, GH is priced at $44.42, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas PMD's P/E ratio is -5.24. In terms of profitability, GH's ROE is +3.69%, compared to PMD's ROE of -0.33%. Regarding short-term risk, GH is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PMD's competition here
GH vs ME Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, GH is priced at $44.42, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ME's P/E ratio is -0.03. In terms of profitability, GH's ROE is +3.69%, compared to ME's ROE of -3.99%. Regarding short-term risk, GH is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ME's competition here
GH vs BNGO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BNGO has a market cap of 11.4M. Regarding current trading prices, GH is priced at $44.42, while BNGO trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BNGO's P/E ratio is -0.06. In terms of profitability, GH's ROE is +3.69%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, GH is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNGO's competition here
GH vs INBS Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, INBS has a market cap of 11.1M. Regarding current trading prices, GH is priced at $44.42, while INBS trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas INBS's P/E ratio is -1.21. In terms of profitability, GH's ROE is +3.69%, compared to INBS's ROE of -1.72%. Regarding short-term risk, GH is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check INBS's competition here
GH vs ADVB Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ADVB has a market cap of 10.8M. Regarding current trading prices, GH is priced at $44.42, while ADVB trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ADVB's P/E ratio is -3.12. In terms of profitability, GH's ROE is +3.69%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, GH is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ADVB's competition here
GH vs BIAFW Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BIAFW has a market cap of 10.4M. Regarding current trading prices, GH is priced at $44.42, while BIAFW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BIAFW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, GH is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check BIAFW's competition here
GH vs BIAF Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BIAF has a market cap of 9.5M. Regarding current trading prices, GH is priced at $44.42, while BIAF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BIAF's P/E ratio is -0.47. In terms of profitability, GH's ROE is +3.69%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, GH is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIAF's competition here
GH vs CNTG Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CNTG has a market cap of 9.2M. Regarding current trading prices, GH is priced at $44.42, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GH's ROE is +3.69%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GH is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CNTG's competition here
GH vs BGLC Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BGLC has a market cap of 8.8M. Regarding current trading prices, GH is priced at $44.42, while BGLC trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BGLC's P/E ratio is -4.12. In terms of profitability, GH's ROE is +3.69%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, GH is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BGLC's competition here
GH vs MYNZ Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MYNZ has a market cap of 7.8M. Regarding current trading prices, GH is priced at $44.42, while MYNZ trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MYNZ's P/E ratio is -0.09. In terms of profitability, GH's ROE is +3.69%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, GH is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYNZ's competition here
GH vs BNR Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BNR has a market cap of 7.3M. Regarding current trading prices, GH is priced at $44.42, while BNR trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BNR's P/E ratio is -2.11. In terms of profitability, GH's ROE is +3.69%, compared to BNR's ROE of -0.39%. Regarding short-term risk, GH is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNR's competition here
GH vs TRIB Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, TRIB has a market cap of 7M. Regarding current trading prices, GH is priced at $44.42, while TRIB trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas TRIB's P/E ratio is -0.38. In terms of profitability, GH's ROE is +3.69%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, GH is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TRIB's competition here
GH vs STRR Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, STRR has a market cap of 6.8M. Regarding current trading prices, GH is priced at $44.42, while STRR trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas STRR's P/E ratio is -0.71. In terms of profitability, GH's ROE is +3.69%, compared to STRR's ROE of -0.24%. Regarding short-term risk, GH is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check STRR's competition here
GH vs NVTA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GH is priced at $44.42, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GH's ROE is +3.69%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GH is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NVTA's competition here
GH vs LMDX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GH is priced at $44.42, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GH's ROE is +3.69%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDX's competition here
GH vs LMDXW Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GH is priced at $44.42, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +3.69%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDXW's competition here
GH vs NDRA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, NDRA has a market cap of 5M. Regarding current trading prices, GH is priced at $44.42, while NDRA trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas NDRA's P/E ratio is 0.02. In terms of profitability, GH's ROE is +3.69%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, GH is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NDRA's competition here
GH vs CHEK Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, CHEK has a market cap of 4.4M. Regarding current trading prices, GH is priced at $44.42, while CHEK trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas CHEK's P/E ratio is -0.36. In terms of profitability, GH's ROE is +3.69%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, GH is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CHEK's competition here
GH vs DMTK Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GH is priced at $44.42, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GH's ROE is +3.69%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, GH is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DMTK's competition here
GH vs AWH Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, GH is priced at $44.42, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas AWH's P/E ratio is -0.09. In terms of profitability, GH's ROE is +3.69%, compared to AWH's ROE of +4.66%. Regarding short-term risk, GH is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check AWH's competition here
GH vs ISPC Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, GH is priced at $44.42, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas ISPC's P/E ratio is -0.09. In terms of profitability, GH's ROE is +3.69%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, GH is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ISPC's competition here
GH vs APDN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, APDN has a market cap of 2.6M. Regarding current trading prices, GH is priced at $44.42, while APDN trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas APDN's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to APDN's ROE of -2.81%. Regarding short-term risk, GH is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check APDN's competition here
GH vs SQL Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GH is priced at $44.42, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas SQL's P/E ratio is -0.40. In terms of profitability, GH's ROE is +3.69%, compared to SQL's ROE of +10.89%. Regarding short-term risk, GH is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SQL's competition here
GH vs HTGM Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GH is priced at $44.42, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GH's ROE is +3.69%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GH is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check HTGM's competition here
GH vs BIOC Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GH is priced at $44.42, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GH's ROE is +3.69%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GH is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIOC's competition here
GH vs TTOO Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, TTOO has a market cap of 426.3K. Regarding current trading prices, GH is priced at $44.42, while TTOO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas TTOO's P/E ratio is -0.51. In terms of profitability, GH's ROE is +3.69%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, GH is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check TTOO's competition here
GH vs OPGN Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, OPGN has a market cap of 392.7K. Regarding current trading prices, GH is priced at $44.42, while OPGN trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas OPGN's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, GH is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check OPGN's competition here
GH vs SQLLW Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, GH is priced at $44.42, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, GH's ROE is +3.69%, compared to SQLLW's ROE of -42.96%. Regarding short-term risk, GH is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check SQLLW's competition here
GH vs OCDX Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GH is priced at $44.42, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GH's ROE is +3.69%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OCDX's competition here
GH vs DHR-PA Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GH is priced at $44.42, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GH's ROE is +3.69%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PA's competition here
GH vs MEUSW Comparison July 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 5.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GH is priced at $44.42, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -13.10, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GH's ROE is +3.69%, compared to MEUSW's ROE of -3.99%. Regarding short-term risk, GH is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MEUSW's competition here